JPRN-jRCT2041210101进行中（未招募）2 期
A placebo-controlled, double-blind crossover study investigating the ameliorative effect of shakuyakukanzoto on paclitaxel (Tri-weekly)-induced muscle pain and arthralgia
akashima Akitoshi0 个研究点目标入组 26 人开始时间: 2021年11月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •[Inclusion Criteria at Provisional Registration]
- •(1) Who plans paclitaxel administered tri-weekly.
- •(2) The age at the date of consent acquisition is 20 years or older
- •(3) The patient's written consent to participate in the study has been obtained.
- •(4) Patients that can be expected to survive for 12 weeks or more .
- •(5) Performance Status (ECOG scale) is 0-2
- •(6) Who have never been treated with chemotherapy including paclitaxel previously.
- •[Inclusion Criteria at Main Registration]
- •(1) Who experienced myalgia or arthralgia above 2 with the pain scale for myalgia or arthralgia during the screening period.
- •(2) Patients in which treatment of paclitaxel can be continued at least 2 courses from the main registration (First course to 3rd course treatment of paclitaxel is mandatory)
- •(3) Patients who can be taken oral administration
- •(4) Patients who meets the all inclusion criteria of provisional registration at the time of main registration and do not conflict with any of the exclusion criteria
排除标准
- •Patients who meet any criterion bellow are excluded from provisional or main registration.
- •(1) Brain metastasis or suspected brain metastasis *1
- •(2) Pleural effusion, ascites, or pericardial fluid which needs treatment.
- •(3) Double cancer except for recovered past cancer
- •(4) Severe allergic or hypersensitive conditions for any drug
- •(5) Hypertension above 170/110 mmHg
- •(6) Severe interstitial pneumoniae, pulmonary fibrosis, or severe COPD
- •(7) Severe comorbidity such as ileus, diabetes mellitus (HbA1c 10.0% and above), heart failure, kidney diseases (serum Cr 1.5 mg/dL and above), liver diseases (AST and/or ALT more than 3 times standard value), or severe heart diseases *3
- •(8) Current thrombosis or embolism
- •(9) Current or past stroke except for asymptomatic lacunar infarction
- •(10) Patients who is taking loop diuretic, thiazido, or any other drug containing shakuyaku, paeoniflorin, kanzo, or glycyrrhizic acid.
- •(11) Serum potassium level below 3.5 mEq/L
- •(12) Aldosteronism
- •(13) Myalgia or arthralgia caused by other diseases *4
- •(14) Myopathy
- •(15) Mental disorders which matter clinically
- •(16) Patients who have taken shakuyakukanzoto previously.
- •(17) Pregnant, lactating, or women with a positive pregnancy test (serum human chorionic gonadotropin (hCG) test).However, pregnancy tests are not required for women undergoing sterilization, women who have had their uterus or both ovaries removed, and women who have been amenorrhea for more than a year without any other medical reason.
- •(18) Patients (male and female) who do not consent to contraception during the period from the acquisition of consent to the end of the clinical trial, or who do not agree to contraception for a period of 6 months or more from the end of the clinical trial as directed by the principal investigator (subinvestigator).
- •(19) Other patients who are judged by the principal investigator to be inappropriate for participation in the study safely.
- •*1 If there are no symptoms, registration is possible even if the presence or absence of brain metastasis has not been confirmed by imaging examination. . However, asymptomatic patients who show brain metastasis in any imaging examination are excluded.
- •*2 The eligibility of the cases with interstitial pneumoniae is judged from the estimation of the risk of worsening due to the drug based on the area of the fibrosis and whether the UIP pattern exists or not. The radiation pneumonitis without symptom is eligible.
- •*3 For example, symptomatic coronary artery diseases, uncontrolled arrhythmia, and myocardial infarction within 12 months.
- •*4 For example, neurologic or muscular diseases which cause chronic or unexpected pain, such as rheumatoid arthritis, guillain-barre syndrome, or chronic inflammatory demyelinating polyneuropathy.
研究者
相似试验
已完成
2 期
The use of APL510 to improve the length of day time sleep in subjects working permanent night-shiftsMental and Behavioural DisordersNonorganic sleep disordersInsomniaISRCTN15733268Alliance Pharmaceuticals Ltd (UK)44
已完成
2 期
1.5 versus 3.0 mg APL510 to normalise sleep patterns in elderly subjects with insomniaMental and Behavioural DisordersNonorganic sleep disordersInsomniaISRCTN82088636Alliance Pharmaceuticals Ltd (UK)80
进行中（未招募）
1 期
A double-blind placebo-controlled cross-over study to determine if melatonin can improve the length of day time sleep in subjects with transient misalignment of the sleep-wake cycle as a result of working permanent night shifts.Transient misalignment of the sleep-wake cycle as a result of working night shifts (insomnia in night shift workers)EUCTR2005-000120-17-GBAlliance Pharmaceuticals Ltd60
撤回
不适用
A double blind placebo-controlled crossover study to determine the effects of atomoxetine on event-related potentials in response to auditory oddball stimuli during an on-the-road driving test in adult patients with attention-deficit hyperactivity disorderADHD10009841Attention Deficit Hyperactivity DisorderNL-OMON31557niversiteit Utrecht30
进行中（未招募）
1 期
A double-blind placebo controlled cross-over study to determine if 1.5 and 3mg of APL510 can normalise sleep patterns in elderly subjects with difficulty in maintenance of sleep and/or initiating sleep onset. - N/AEUCTR2004-003939-32-GBAlliance Pharmaceuticals Ltd80